Research programme: anti-CD3 clinical imaging - ImaginAb/MacroGenics
Latest Information Update: 16 Feb 2016
At a glance
- Originator ImaginAb; MacroGenics
- Developer ImaginAb Inc
- Class Antibody diagnostics; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 16 Feb 2016 Discontinued - Preclinical for Autoimmune disorders (Diagnosis) in USA (Parenteral)
- 16 Feb 2016 Discontinued - Preclinical for Cancer (Diagnosis) in USA (Parenteral)
- 10 Apr 2014 Preclinical trials in Autoimmune disorders (diagnosis) in USA before April 2014 (Parenteral)